nvsi-06-08
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 14, 2021 (NCT05069129)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05069129 | Phase 1/Phase 2 (Phase 2) | Oct 14, 2021 | Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, National Vaccine and Serum Institute, China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Tiantan Bio Co., Ltd | For profit | 1 | 0 | 1 | 2021 |
| China National Biotec Group Co., Ltd | For profit | 1 | 0 | 1 | 2021 |
| National Vaccine and Serum Institute, China | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1